5 January 2020
Inovio and Advaccine Biopharmaceuticals announced that they have entered into a collaborative agreement to commercialise INO-4800, a Covid-19 DNA vaccine candidate. As per the terms of the agreement, Advaccine will develop, manufacture and commercialise the vaccine across Greater China, including Mainland China, Macao, Hong Kong, and Taiwan. The company will also make an upfront payment of $3m to Inovio and an aggregate of $108m for achieving its specified milestones for INO-4800 in Greater China.
Moderna announced that Israel has authorised Moderna’s Covid-19 vaccine. This marks the third regulatory authorisation of the company’s vaccine candidate, and the first outside of North America. The country has sought six million doses of the Moderna Covid-19 vaccine, with first deliveries expected to commence soon.
aTyr Pharma has announced positive topline results from its Phase II double-blind, placebo-controlled clinical trial of ATYR1923, its lead therapeutic candidate for treating hospitalised Covid-19 patients suffering severe respiratory conditions and who do not require mechanical ventilation. The trial met its safety endpoint and showed that a single, intravenous dose of ATYR1923 was safe and also well-tolerated among 1.0 and 3.0 mg/kg treatment groups.
Arcturus Therapeutics has sought US Food and Drug Administration (FDA) approval of the Investigational New Drug application to proceed with its Phase II clinical study of ARCT-021 in the US and Singapore. The study will evaluate single and double doses of the company’s vaccine candidate on approximately 600 participants, with anticipated Phase II data to be released in early 2021.